医疗保险药品价格谈判——为何是现在……以及如何进行。 - Suppr

Suppr

超能文献

Medicare Drug-Price Negotiation - Why Now . . . and How.

作者信息

Frank Richard G, Nichols Len M

机构信息

From Harvard University Medical School, Boston (R.G.F.); and George Mason University, Fairfax, VA (L.M.N.).

出版信息

N Engl J Med. 2019 Oct 10;381(15):1404-1406. doi: 10.1056/NEJMp1909798. Epub 2019 Sep 4.

DOI:10.1056/NEJMp1909798

PMID:31483959

Abstract

摘要

相似文献

Medicare Drug-Price Negotiation - Why Now . . . and How.

N Engl J Med. 2019 Oct 10;381(15):1404-1406. doi: 10.1056/NEJMp1909798. Epub 2019 Sep 4.

Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices.

N Engl J Med. 2019 Oct 10;381(15):1401-1404. doi: 10.1056/NEJMp1908688. Epub 2019 Sep 4.

CMS retreats on Part D rule intended to reduce drug costs and improve access.

Mod Healthc. 2014 Mar 17;44(11):10.

Lowering Part D drug costs without direct CMS negotiations.

Manag Care. 2009 Sep;18(9):11-2.

Advancing Legislation on Drug Pricing - Is There a Path Forward?

N Engl J Med. 2019 Nov 28;381(22):2081-2084. doi: 10.1056/NEJMp1914044.

Pharmaceuticals and medical devices: cost savings.

Issue Brief Health Policy Track Serv. 2009 Jan 5:1-20.

Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.

Issue Brief Health Policy Track Serv. 2008 Jan 7:1-27.

Medicare program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs. Final rule.

Fed Regist. 2014 May 23;79(100):29843-968.

Pharmaceuticals and medical devices: Medicare Part D. Issue brief.

Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.

Specialty Drugs - A Distinctly American Phenomenon.

N Engl J Med. 2020 Jun 4;382(23):2179-2181. doi: 10.1056/NEJMp1909513.

引用本文的文献

Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis.

J Glob Health. 2025 Apr 18;15:04069. doi: 10.7189/jogh.15.04069.

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service.

Pharmacoeconomics. 2023 Jan;41(1):107-117. doi: 10.1007/s40273-022-01215-w. Epub 2022 Nov 25.

Health Care Spending on Respiratory Diseases in the United States, 1996-2016.

Am J Respir Crit Care Med. 2023 Jan 15;207(2):183-192. doi: 10.1164/rccm.202202-0294OC.

Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Value Health. 2022 Jul;25(7):1141-1147. doi: 10.1016/j.jval.2021.11.1375. Epub 2022 Feb 24.

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.

Int J Health Policy Manag. 2022 Aug 1;11(8):1489-1495. doi: 10.34172/ijhpm.2021.47. Epub 2021 Jun 9.

Value-based drug pricing in the Biden era: Opportunities and prospects.

Health Serv Res. 2021 Dec;56(6):1093-1099. doi: 10.1111/1475-6773.13686. Epub 2021 Jun 3.

Government royalties on sales of biomedical products developed with substantial public funding.

J Technol Transf. 2021;46(5):1321-1343. doi: 10.1007/s10961-020-09821-6. Epub 2020 Aug 19.

Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries.

JAMA Netw Open. 2020 Jun 1;3(6):e208968. doi: 10.1001/jamanetworkopen.2020.8968.

Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.

JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.

JAMA Cardiol. 2020 Mar 1;5(3):336-339. doi: 10.1001/jamacardio.2019.4982.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Medicare Drug-Price Negotiation - Why Now . . . and How.

作者信息

Frank Richard G, Nichols Len M

机构信息

From Harvard University Medical School, Boston (R.G.F.); and George Mason University, Fairfax, VA (L.M.N.).

出版信息

N Engl J Med. 2019 Oct 10;381(15):1404-1406. doi: 10.1056/NEJMp1909798. Epub 2019 Sep 4.

DOI:10.1056/NEJMp1909798

PMID:31483959

Abstract

摘要

相似文献

Medicare Drug-Price Negotiation - Why Now . . . and How.

N Engl J Med. 2019 Oct 10;381(15):1404-1406. doi: 10.1056/NEJMp1909798. Epub 2019 Sep 4.

Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices.

N Engl J Med. 2019 Oct 10;381(15):1401-1404. doi: 10.1056/NEJMp1908688. Epub 2019 Sep 4.

CMS retreats on Part D rule intended to reduce drug costs and improve access.

Mod Healthc. 2014 Mar 17;44(11):10.

Lowering Part D drug costs without direct CMS negotiations.

Manag Care. 2009 Sep;18(9):11-2.

Advancing Legislation on Drug Pricing - Is There a Path Forward?

N Engl J Med. 2019 Nov 28;381(22):2081-2084. doi: 10.1056/NEJMp1914044.

Pharmaceuticals and medical devices: cost savings.

Issue Brief Health Policy Track Serv. 2009 Jan 5:1-20.

Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.

Issue Brief Health Policy Track Serv. 2008 Jan 7:1-27.

Medicare program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs. Final rule.

Fed Regist. 2014 May 23;79(100):29843-968.

Pharmaceuticals and medical devices: Medicare Part D. Issue brief.

Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.

Specialty Drugs - A Distinctly American Phenomenon.

N Engl J Med. 2020 Jun 4;382(23):2179-2181. doi: 10.1056/NEJMp1909513.

引用本文的文献

Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis.

J Glob Health. 2025 Apr 18;15:04069. doi: 10.7189/jogh.15.04069.

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service.

Pharmacoeconomics. 2023 Jan;41(1):107-117. doi: 10.1007/s40273-022-01215-w. Epub 2022 Nov 25.

Health Care Spending on Respiratory Diseases in the United States, 1996-2016.

Am J Respir Crit Care Med. 2023 Jan 15;207(2):183-192. doi: 10.1164/rccm.202202-0294OC.

Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Value Health. 2022 Jul;25(7):1141-1147. doi: 10.1016/j.jval.2021.11.1375. Epub 2022 Feb 24.

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.

Int J Health Policy Manag. 2022 Aug 1;11(8):1489-1495. doi: 10.34172/ijhpm.2021.47. Epub 2021 Jun 9.

Value-based drug pricing in the Biden era: Opportunities and prospects.

Health Serv Res. 2021 Dec;56(6):1093-1099. doi: 10.1111/1475-6773.13686. Epub 2021 Jun 3.

Government royalties on sales of biomedical products developed with substantial public funding.

J Technol Transf. 2021;46(5):1321-1343. doi: 10.1007/s10961-020-09821-6. Epub 2020 Aug 19.

Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries.

JAMA Netw Open. 2020 Jun 1;3(6):e208968. doi: 10.1001/jamanetworkopen.2020.8968.

Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.

JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.

JAMA Cardiol. 2020 Mar 1;5(3):336-339. doi: 10.1001/jamacardio.2019.4982.